Sign inJoin waitlistJoin the waitlist

CC

Clinton Carroll

Physician · TriStar Centennial Medical Center

Credentials: · · · · ·

History

TriStar Centennial Medical Center
2020–Present

Pediatric Hematology-Oncology
University of Mississippi School of Medicine
2011–2012
Pediatrics
Vanderbilt University Medical Center
2008–2011
Vanderbilt University School of Medicine
2004–2008

Research

ATR phosphorylates SMARCAL1 to prevent replication fork collapse
Genes & Development · 2013 · 345 citations
ETAA1 acts at stalled replication forks to maintain genome integrity
Nature Cell Biology · 2016 · 210 citations
Schimke Immunoosseous Dysplasia associated with undifferentiated carcinoma and a novel SMARCAL1 mutation in a child
Case report · Pediatric Blood & Cancer · 2013 · First of 6 authors · Corresponding · 25 citations

HF
Haydar Frangoul
5 papers
MM
Meghann Mcmanus
4 papers
JD
Jennifer Domm
3 papers
Alexis Thompson
2 papers
Scott Borinstein
2 papers
Tracy Hunley
2 papers
Akiko Shimamura
1 paper
Alan D’Andrea
1 paper
Amy Hont
1 paper
Annette Kim
1 paper · 1 as a fellow
Ashley Chadha
1 paper · 1 as a fellow
Ashley Galvin
1 paper

Clinical trials

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
Site PI · Recruiting · Phase 3
Children's Oncology Group
2026–2033
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2026–2031
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030